Physician profile
Kyle Magee Bennett
NPI 1740623115
$1,479.33
in general payments reported to CMS, 2019-2025
15 companies · $592 in 2025
The $592 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.08 · 2023: $164 · 2024: $699 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $591.17 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $199.89 | 2023-2025 | Rybelsus, Ozempic, Tresiba |
| Exact Sciences Corporation | $119.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $108.94 | 2024 | Rexulti |
| Dexcom, INC. | $69.69 | 2023-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $67.46 | 2025 | Inspire |
| Amgen INC. | $58.00 | 2024-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $56.34 | 2024-2025 | Veozah |
| Merck Sharp & Dohme LLC | $49.48 | 2025 | Lagevrio |
| Esperion Therapeutics, INC. | $43.24 | 2025 | Nexletol |
| Pfizer INC. | $35.99 | 2023-2025 | |
| Ascensia Diabetes Care US INC. | $25.07 | 2025 | |
| Abbott Laboratories | $24.08 | 2022 | |
| Glaxosmithkline, LLC. | $15.71 | 2024 | Trelegy Ellipta |
| Currax Pharmaceuticals LLC | $14.32 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.